Compare COFS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COFS | REPL |
|---|---|---|
| Founded | 1898 | 2015 |
| Country | United States | United States |
| Employees | 598 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.2M | 407.1M |
| IPO Year | 1995 | 2018 |
| Metric | COFS | REPL |
|---|---|---|
| Price | $31.45 | $8.60 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 9 |
| Target Price | ★ $34.00 | $5.67 |
| AVG Volume (30 Days) | 54.0K | ★ 6.0M |
| Earning Date | 04-24-2026 | 05-21-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | N/A | ★ 5.25 |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $227,624,000.00 | N/A |
| Revenue This Year | $22.13 | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $34.42 | ★ N/A |
| Revenue Growth | ★ 63.64 | N/A |
| 52 Week Low | $26.10 | $1.50 |
| 52 Week High | $33.58 | $13.24 |
| Indicator | COFS | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 57.61 | 76.20 |
| Support Level | $29.51 | $8.24 |
| Resistance Level | $32.43 | $9.01 |
| Average True Range (ATR) | 0.68 | 0.65 |
| MACD | 0.00 | 0.34 |
| Stochastic Oscillator | 67.05 | 95.38 |
ChoiceOne Financial Services Inc is a full-service banking institution. It is engaged in the business of providing personal and business banking solutions, borrowing solutions, and treasury notes and bonds services. The bank's product and services portfolio consist of time, savings and demand deposits, safe deposit services, automated transaction machine services, commercial and consumer loans, commercial lending to business, industry, agricultural, construction, inventory, and real estate categories. Its primary market area is Kent, Muskegon, Newaygo, and Ottawa counties in western Michigan, and Lapeer, Macomb, and St. Clair counties in southeastern Michigan in the communities where the Bank's respective offices are located.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.